1.Shaib WL, Goodman M, Chen Z, Kim S, Brutcher E, Bekaii-Saab T, et al. Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. American journal of clinical oncology. 2015 Aug 11. PubMed PMID: 26270447. Epub 2015/08/14. Eng.
2.Misdraji J. Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei. Mod Pathol. 2015 Jan;28 Suppl 1:S67–79. PubMed PMID: 25560600.
3.Noguchi R, Yano H, Gohda Y, Suda R, Igari T, Ohta Y, et al. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer medicine. 2015 Dec;4(12):1809–16. PubMed PMID: 26475379. Pubmed Central PMCID: 5123786.
4.Nummela P, Saarinen L, Thiel A, Jarvinen P, Lehtonen R, Lepisto A, et al. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer. 2015 Mar 01;136(5):E282–9. PubMed PMID: 25274248.
5.Singhi AD, Davison JM, Choudry HA, Pingpank JF, Ahrendt SA, Holtzman MP, et al. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Human pathology. 2014 Aug;45(8):1737–43. PubMed PMID: 24925222.
6.Sio TT, Mansfield AS, Grotz TE, Graham RP, Molina JR, Que FG, et al. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. Journal of human genetics. 2014 Mar;59(3):124–8. PubMed PMID: 24369359. Pubmed Central PMCID: 3973125.
7.Liu X, Mody K, de Abreu FB, Pipas JM, Peterson JD, Gallagher TL, et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clinical chemistry. 2014 Jul;60(7):1004–11. PubMed PMID: 24821835.
8.Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome medicine. 2014;6(5):43. PubMed PMID: 24944587. Pubmed Central PMCID: 4062050.
9.Shih IM, Yan H, Speyrer D, Shmookler BM, Sugarbaker PH, Ronnett BM. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei. The American journal of surgical pathology. 2001 Aug;25(8):1095–9. PubMed PMID: 11474297.
10.Racek AR, Rabe KG, Wick MJ, Psychogios A, Lindor NM. Primary appendiceal mucinous adenocarcinoma in two first-degree relatives: case report and review. Hereditary cancer in clinical practice. 2011 May 04;9(1):1. PubMed PMID: 21542938. Pubmed Central PMCID: 3098790.
11.FastQC: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
12.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal; Vol 17, No 1: Next Generation Sequencing Data Analysis. 2011 05/02/.
13.Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013 (arXiv:1303.3997v2 [q-bio.GN].)
14.Picard: http://broadinstitute.github.io/picard
15.McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research. 2010 Sep;20(9):1297–303. PubMed PMID: 20644199. Pubmed Central PMCID: 2928508.
16.McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010 Aug 15;26(16):2069–70. PubMed PMID: 20562413. Pubmed Central PMCID: 2916720.
17.Rios D, McLaren WM, Chen Y, Birney E, Stabenau A, Flicek P, et al. A database and API for variation, dense genotyping and resequencing data. BMC bioinformatics. 2010 May 11;11:238. PubMed PMID: 20459810. Pubmed Central PMCID: 2882931.
18.Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012 Nov 01;491(7422):56–65. PubMed PMID: 23128226. Pubmed Central PMCID: 3498066.
19.Exome Variant Server. NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) n.d.
20.Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DYH, Tothill RW, et al. Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles. PLoS Genetics. 2012;8(9).
21.Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic acids research. 2002 Sep 01;30(17):3894–900. PubMed PMID: 12202775. Pubmed Central PMCID: 137415.
22.Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic acids research. 2003 Jul 01;31(13):3812–4. PubMed PMID: 12824425. Pubmed Central PMCID: 168916.
23.Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014 Mar;46(3):310–5. PubMed PMID: 24487276. Pubmed Central PMCID: 3992975.
24.Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotech. 2011 01//print;29(1):24–6.
25.Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Briefings in Bioinformatics. 2013;14(2):178–92.
26.Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016 08/18/print;536(7616):285–91.
27.Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3—new capabilities and interfaces. Nucleic acids research. 2012 Aug;40(15):e115. PubMed PMID: 22730293. Pubmed Central PMCID: 3424584.
28.Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23(10):1289–91.
29.Thomas NA, Neville PJ, Baxter SW, Campbell IG. Genetic analysis of benign ovarian tumors. Int J Cancer. 2003 Jul 01;105(4):499–505. PubMed PMID: 12712441.
30.Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. The Lancet Oncology. 2011 Jan;12(1):49–55. PubMed PMID: 21145788. Pubmed Central PMCID: 3670774.
31.Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013 Feb;45(2):136–44. PubMed PMID: 23263490. Pubmed Central PMCID: 3785128.
32.de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L, et al. Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. Gastroenterology. 2013 Sep;145(3):544–7. PubMed PMID: 23747338. Epub 2013/06/12. eng.
33.Rio Frio T, Lavoie J, Hamel N, Geyer FC, Kushner YB, Novak DJ, et al. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. The New England journal of medicine. 2010 Dec 30;363(27):2628–37. PubMed PMID: 21190457.
34.Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet. 2015 Jun;47(6):668–71. PubMed PMID: 25938944.
35.KOOREY D, BASHA NJ, TOMARAS C, FREIMAN J, ROBSON L, SMITH A. Appendiceal carcinoma complicating adenomatous polyposis in a young woman with a de novo constitutional reciprocal translocation t(5;8)(q22;p23.1). Journal of Medical Genetics. 2000;37(1):71–5.
36.Shin SM, Chung YJ, Oh ST, Jeon HM, Hwang LJ, Namkoong H, et al. HCCR–1-interacting molecule “deleted in polyposis 1” plays a tumor-suppressor role in colon carcinogenesis. Gastroenterology. 2006 Jun;130(7):2074–86. PubMed PMID: 16762630.
37.Ko J, Lee YH, Hwang SY, Lee YS, Shin SM, Hwang JH, et al. Identification and differential expression of novel human cervical cancer oncogene HCCR–2 in human cancers and its involvement in p53 stabilization. Oncogene. 2003 Jul 24;22(30):4679–89. PubMed PMID: 12879013.
38.Burke B. PREEParing for mitosis. Developmental cell. 2013 Aug 12;26(3):221–2. PubMed PMID: 23948250.
39.Camargo AC, Gomes MD, Reichl AP, Ferro ES, Jacchieri S, Hirata IY, et al. Structural features that make oligopeptides susceptible substrates for hydrolysis by recombinant thimet oligopeptidase. The Biochemical journal. 1997 Jun 01;324 ( Pt 2):517–22. PubMed PMID: 9182712. Pubmed Central PMCID: PMC1218460. Epub 1997/06/01. eng.
40.Nomoto S, Hishida M, Inokawa Y, Takano N, Kanda M, Nishikawa Y, et al. Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis. Ann Surg Oncol. 2014 Jun;21 Suppl 3:S443–50. PubMed PMID: 24604581. Epub 2014/03/08. eng.
41.Cheng T-L, Lai C-H, Jiang S-J, Hung J-H, Liu S-K, Chang B-I, et al. RHBDL2 Is a Critical Membrane Protease for Anoikis Resistance in Human Malignant Epithelial Cells. The Scientific World Journal. 2014;2014:8.
42.Katoh M, Nakagama H. FGF Receptors: Cancer Biology and Therapeutics. Medicinal Research Reviews. 2014;34(2):280–300.
43.Xu W, Li Y, Wang X, Chen B, Wang Y, Liu S, et al. FGFR4 transmembrane domain polymorphism and cancer risk: A meta-analysis including 8555 subjects. European journal of cancer. 2010 2010/12/01/;46(18):3332–8.
44.Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004 May 20;350(21):2129–39. PubMed PMID: 15118073. Epub 2004/05/01. eng.
45.Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology. 2012 Mar;13(3):239–46. PubMed PMID: 22285168. Epub 2012/01/31. eng.
46.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG–0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology. 2011 Aug;12(8):735–42. PubMed PMID: 21783417. Epub 2011/07/26. eng.
47.Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine. 2009;361(10):947–57. PubMed PMID: 19692680.